Credit: Image source: Getty Images.What happened
Shares of China Biologic Products (NASDAQ: CBPO) rose nearly 15% today after the company announced that it has received its second buyout offer of the summer.
In June, Chinese investment firm CITIC Capital proposed an all-cash offer to gobble up the blood plasma product leader for $110 per share. Now, a group of investors led by the company's former CEO, David Gao, has made an all-cash offer to do the same, but this time at $118 per share. The deal would value the company at $3.9 billion.
As of 12:32 p.m. EDT, the stock had settled to a 11% gain at around $102 per share.
Image source: Getty Images.
So what
Despite a growing business and enormous market opportunity in its home country, China Biologic Products has not been able to grow its share price beyond $120, a level first reached in 2015. While that was a premium valuation for the business at the time, it has since grown into its $3 billion-plus market cap. Nonetheless, signs of slowing growth on the bottom line pushed shares below $80 apiece earlier this year.
That drew the attention of China-based institutional investors. They think there's plenty of opportunity in the fledgling blood plasma products market in China. Despite relying on decades-old technology that the United States began moving away from in the 1970s, the groups jockeying for ownership of China Biologic Products might be right about the opportunity, especially from a financial perspective. After all, the business earned a 69% gross profit margin in the first half of 2018.
Now what
The emergence of a bidding war is good news for shareholders. Now, all investors can do is wait to see who wins and if a deal will be completed at all. Considering there are now two groups interested in owning China Biologic Products (both at a stock price significantly higher than current levels) and that all groups involved are Chinese (making it easier to pass regulatory scrutiny), there's a good chance that occurs.
10 stocks we like better than China Biologic Products
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and China Biologic Products wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
